- Significant reduction of key cytokines IL-31, IL-36α, and IL-36γ - ISGA mean score of 0.83 with GX-03 topical pre-treatment vs 2.44 placebo, comparable to biologics - Company projects phase 1b /2 efficacy trials to begin in 2025 WESTLAKE VILLAGE, Calif.
, Aug. 5, 2024 /PRNewswire/ -- Turn Therapeutics , a pharmaceutical and medical device company focused on immunology, advanced wound care, and dermatology, announced today positive data results of GX-03 in a biomarker study intended to measure its immunological inhibitory effects during eczema induction. The study evaluated the immunological inhibitory effects of the topical application of Turn Therapeutics' candidate, GX-03, in an eczema model using C57BL/6 mice and a well-established NIH pre-treatment protocol.
After a four-day pretreatment period with GX-03, disease induction was carried out over the following three days. Cytokine levels and average disease severity scores were then assessed using the ISGA (Investigator's Static Global Assessment) scale across all groups. GX-03 showed inhibition of key cytokines implicated in multiple dermatological conditions, including atopic dermatitis.
IL-31 levels, considered to play a significant role in the pathogenesis of eczema and atopic dermatitis (AD), showed a reduction of 67.7% vs placebo [p-value (1.12×10 −6 )].
IL-36α and IL-36γ also demonstrated significant inhibition: 50% [p-value (3.0×10 −6 )] and 49% [4.35×10 −8 ], respectively.
IL-36α is a key cytokine d.